Search

Your search keyword '"Persano, Mara"' showing total 155 results
Start Over Author "Persano, Mara"
155 results on '"Persano, Mara"'

1. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Rossari, Federico, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo Alberto, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Soldà, Caterina, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Bruccoleri, Mariangela, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Foti, Silvia, Camera, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

2. Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Author

Rimini, Margherita, Montes, Margarida, Amadeo, Elisabeth, Vitiello, Francesco, Kudo, Masatoshi, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Lonardi, Sara, Finkelmeier, Fabian, Salani, Francesca, Antonuzzo, Lorenzo, Marra, Fabio, Iavarone, Massimo, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Sacco, Rodolfo, Rapposelli, Ilario Giovanni, Scartozzi, Mario, Nicoletta, Pella, Aldrighetti, Luca, Persano, Mara, Camera, Silvia, Rossari, Federico, Foti, Silvia, Kumada, Takashi, Hiraoka, Atsushi, Iwamoto, Hideki, Rizzato, Mario Domenico, Himmelsbach, Vera, Masi, Gianluca, Corradi, Mattia, Celsa, Ciro, Fabio, Conti, Frassineti, Giovanni Luca, Cascinu, Stefano, Casadei-Gardini, Andrea, and Presa, Jose

Published
2024
Full Text
View/download PDF

3. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

Author

Rimini, Margherita, Loi, Eleonora, Rizzato, Mario Domenico, Pressiani, Tiziana, Vivaldi, Caterina, Gusmaroli, Eleonora, Antonuzzo, Lorenzo, Martinelli, Erika, Garajova, Ingrid, Giordano, Guido, Lucchetti, Jessica, Schirripa, Marta, Cornara, Noemi, Rossari, Federico, Vitiello, Francesco, Amadeo, Elisabeth, Persano, Mara, Piva, Vittoria Matilde, Balsano, Rita, Salani, Francesca, Pircher, Chiara, Cascinu, Stefano, Niger, Monica, Fornaro, Lorenzo, Rimassa, Lorenza, Lonardi, Sara, Scartozzi, Mario, Zavattari, Patrizia, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

4. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Author

Camera, Silvia, Rimini, Margherita, Rossari, Federico, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Salani, Francesca, Marseglia, Mariarosaria, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Lonardi, Sara, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Persano, Mara, Foti, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

5. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors

Author

Ziranu, Pina, Pretta, Andrea, Pozzari, Marta, Maccioni, Antonio, Badiali, Manuela, Fanni, Daniela, Lai, Eleonora, Donisi, Clelia, Persano, Mara, Gerosa, Clara, Puzzoni, Marco, Bardanzellu, Fabio, Ambu, Rossano, Pusceddu, Valeria, Dubois, Marco, Cerrone, Giulia, Migliari, Marco, Murgia, Sara, Spanu, Dario, Pretta, Gianluca, Aimola, Valentina, Balconi, Francesca, Murru, Stefania, Faa, Gavino, and Scartozzi, Mario

Published
2023
Full Text
View/download PDF

6. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Salani, Francesca, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Schirripa, Marta, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

7. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Kawaguchi, Takumi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Cammarota, Antonella, Burgio, Valentina, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

8. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Rimassa, Lorenza, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

9. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients

Author

Rimini, Margherita, Fabregat-Franco, Carles, Persano, Mara, Burgio, Valentina, Bergamo, Francesca, Niger, Monica, Scartozzi, Mario, Rapposelli, Ilario Giovanni, Aprile, Giuseppe, Ratti, Francesca, Pedica, Federica, Verdaguer, Helena, Rizzato, Mario, Nichetti, Federico, Lai, Eleonora, Cappetta, Alessandro, Macarulla, Teresa, Fassan, Matteo, De Braud, Filippo, Pretta, Andrea, Simionato, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Fornaro, Lorenzo, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

10. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Niizeki, Takashi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Stefanini, Bernardo, Hiraoka, Atsushi, Sho, Takuya, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Campani, Claudia, Amadeo, Elisabeth, Rossari, Federico, Burgio, Valentina, Cascinu, Stefano, Scartozzi, Mario, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

11. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis

Author

Rimini, Margherita, Burgio, Valentina, Antonuzzo, Lorenzo, Rimassa, Lorenza, Oneda, Ester, Lavacchi, Daniele, Personeni, Nicola, Ratti, Francesca, Pedica, Federica, Della Corte, Angelo, Persano, Mara, De Cobelli, Francesco, Aldrighetti, Luca, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2022
Full Text
View/download PDF

12. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Author

Casadei-Gardini, Andrea, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Persano, Mara, Della Corte, Angelo, Ratti, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Cascinu, Stefano, and Cucchetti, Alessandro

Published
2023
Full Text
View/download PDF

13. Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.

Author

Persano, Mara, Casadei-Gardini, Andrea, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Rossari, Federico, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, and Aoki, Tomoko

Subjects
*CHEMOEMBOLIZATION, *OVERALL survival, *PROGNOSIS, *SORAFENIB, *HEPATOCELLULAR carcinoma
Abstract

Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries is sorafenib, due to the lack of reimbursement for other drugs. Several randomized trials are currently underway to clarify the best second-line therapy in patients with HCC. This real-world study aimed to compare outcomes reached by lenvatinib and sorafenib second-line therapy in this setting. Methods: The overall cohort included 891 patients with HCC from 5 countries treated with atezolizumab plus bevacizumab in first-line setting between October 2018 and April 2022. At the data cut-off (May 2022), 41.5% of patients were continuing a first-line treatment, 5.5% were lost at follow-up, and 53.0% of patients had progressive disease after first-line therapy. 51.5% of patients with progressive disease received a second-line treatment, while 48.5% did not receive any subsequent therapy. Between patients receiving second-line treatment, 11.1% of patients underwent transarterial chemoembolization, 21.0% received sorafenib, 35.4% underwent lenvatinib, and 32.5% were treated with other drugs. Results: Lenvatinib second-line subgroup achieved a median overall survival (mOS) of 18.9 months, significative longer (p = 0.01; hazard ratio [HR]: 2.24) compared to sorafenib subgroup that reached a mOS of 14.3 months. The multivariate analysis highlighted albumin-bilirubin 1 grade (p < 0.01; HR: 5.23) and lenvatinib second-line therapy (p = 0.01; HR: 2.18) as positive prognostic factors for OS. The forest plot highlighted a positive trend in terms of OS in favor of patients treated with lenvatinib second-line regardless of baseline characteristics before first-line therapy. Conclusion: These results suggest that, in patients with HCC progressed to first-line atezolizumab plus bevacizumab, lenvatinib second-line therapy is associated to an improved survival compared to sorafenib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Foti, Silvia, additional, Camera, Silvia, additional, Stefanini, Bernardo, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei-Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2024
Full Text
View/download PDF

15. Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging

Author

Corrias, Giuseppe, primary, Lai, Eleonora, additional, Ziranu, Pina, additional, Mariani, Stefano, additional, Donisi, Clelia, additional, Liscia, Nicole, additional, Saba, Giorgio, additional, Pretta, Andrea, additional, Persano, Mara, additional, Fanni, Daniela, additional, Spanu, Dario, additional, Balconi, Francesca, additional, Loi, Francesco, additional, Deidda, Simona, additional, Restivo, Angelo, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Solinas, Cinzia, additional, Massa, Elena, additional, Madeddu, Clelia, additional, Gerosa, Clara, additional, Zorcolo, Luigi, additional, Faa, Gavino, additional, Saba, Luca, additional, and Scartozzi, Mario, additional

Published
2024
Full Text
View/download PDF

16. BRCA-mutant pancreatic ductal adenocarcinoma

Author

Lai, Eleonora, Ziranu, Pina, Spanu, Dario, Dubois, Marco, Pretta, Andrea, Tolu, Simona, Camera, Silvia, Liscia, Nicole, Mariani, Stefano, Persano, Mara, Migliari, Marco, Donisi, Clelia, Demurtas, Laura, Pusceddu, Valeria, Puzzoni, Marco, and Scartozzi, Mario

Published
2021
Full Text
View/download PDF

17. The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment

Author

Ziranu, Pina, Lai, Eleonora, Schirripa, Marta, Puzzoni, Marco, Persano, Mara, Pretta, Andrea, Munari, Giada, Liscia, Nicole, Pusceddu, Valeria, Loupakis, Fotios, Demurtas, Laura, Libertini, Michela, Mariani, Stefano, Migliari, Marco, Dubois, Marco, Giampieri, Riccardo, Sotgiu, Giovanni, Dei Tos, Angelo Paolo, Lonardi, Sara, Zaniboni, Alberto, Fassan, Matteo, and Scartozzi, Mario

Published
2021
Full Text
View/download PDF

18. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?

Author

Lai, Eleonora, Astara, Giorgio, Ziranu, Pina, Pretta, Andrea, Migliari, Marco, Dubois, Marco, Donisi, Clelia, Mariani, Stefano, Liscia, Nicole, Impera, Valentino, Persano, Mara, Tolu, Simona, Balconi, Francesca, Pinna, Giovanna, Spanu, Dario, Pireddu, Annagrazia, Saba, Giorgio, Camera, Silvia, Musio, Francesca, Puzzoni, Marco, Pusceddu, Valeria, Madeddu, Clelia, Casadei Gardini, Andrea, and Scartozzi, Mario

Published
2021
Full Text
View/download PDF

19. Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents

Author

Amadeo, Elisabeth, Foti, Silvia, Camera, Silvia, Rossari, Federico, Persano, Mara, Lo Prinzi, Federica, Vitiello, Francesco, Casadei-Gardini, Andrea, and Rimini, Margherita

Abstract

ABSTRACTIntroductionHepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the first for primary liver tumors. In recent years greater therapeutic advancement was represented by employment of tyrosine kinase inhibitors (TKIs) either in monotherapy or in combination with immune checkpoint inhibitors (ICIs).Areas coveredMajor attention was given to target therapies in the last couple of years, especially in those currently under phase II trials. Priority was given either to combinations of novel ICI and TKIs or those targeting alternative mutations of major carcinogenic pathways.Expert opinionAs TKIs are playing a more crucial role in HCC therapeutic strategies, it is fundamental to further expand molecular testing and monitoring of acquired resistances. Despite the recent advancement in both laboratory and clinical studies, further research is necessary to face the discrepancy in clinical practice.

Published
2024
Full Text
View/download PDF

20. Treatment options for advanced hepatocellular carcinoma: the potential of biologics

Author

Rossari, Federico, Foti, Silvia, Camera, Silvia, Persano, Mara, Casadei-Gardini, Andrea, and Rimini, Margherita

Abstract

ABSTRACTIntroductionAdvanced hepatocellular carcinoma (HCC) represents a significant global health burden, whose treatment has been recently revolutionized by the advent of biologic treatments. Despite that, innovative therapeutic regimens and approaches, especially immune-based, remain to be explored aiming at extending the therapeutic benefits to a wider population of patients.Areas coveredThis review comprehensively discusses the evolving landscape of biological treatment modalities for advanced HCC, including immune checkpoint inhibitors, antiangiogenic monoclonal antibodies, tumor-targeting monoclonal antibodies either naked or drug-conjugated, therapeutic vaccines, oncolytic viruses, adoptive cell therapies, and cytokine-based therapies. Key clinical trials and preclinical studies are examined, highlighting the actual or potential impact of these interventions in reshaping treatment paradigms for HCC.Expert opinionTailored and rational combination strategies, leveraging the synergistic effects of different modalities, represent a promising approach to maximize treatment efficacy in advanced HCC, which should aim at conversion endpoints to increase the fraction of patients eligible for curative approaches. The identification of predictive biomarkers holds the key to optimizing patient selection and improving therapeutic outcomes.

Published
2024
Full Text
View/download PDF

21. α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Burgio, Valentina, additional, Piscaglia, Fabio, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei‐Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2023
Full Text
View/download PDF

23. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Author

Rimini, Margherita, primary, Fornaro, Lorenzo, additional, Lonardi, Sara, additional, Niger, Monica, additional, Lavacchi, Daniele, additional, Pressiani, Tiziana, additional, Lucchetti, Jessica, additional, Giordano, Guido, additional, Pretta, Andrea, additional, Tamburini, Emiliano, additional, Pirrone, Chiara, additional, Rapposelli, Ilario Giovanni, additional, Diana, Anna, additional, Martinelli, Erika, additional, Garajová, Ingrid, additional, Simionato, Francesca, additional, Schirripa, Marta, additional, Formica, Vincenzo, additional, Vivaldi, Caterina, additional, Caliman, Enrico, additional, Rizzato, Mario Domenico, additional, Zanuso, Valentina, additional, Nichetti, Federico, additional, Angotti, Lorenzo, additional, Landriscina, Matteo, additional, Scartozzi, Mario, additional, Ramundo, Matteo, additional, Pastorino, Alessandro, additional, Daniele, Bruno, additional, Cornara, Noemi, additional, Persano, Mara, additional, Gusmaroli, Eleonora, additional, Cerantola, Riccardo, additional, Salani, Francesca, additional, Ratti, Francesca, additional, Aldrighetti, Luca, additional, Cascinu, Stefano, additional, Rimassa, Lorenza, additional, Antonuzzo, Lorenzo, additional, and Casadei‐Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

25. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

Author

Fabbri, Agnese, primary, Nelli, Fabrizio, additional, Botticelli, Andrea, additional, Giannarelli, Diana, additional, Marrucci, Eleonora, additional, Fiore, Cristina, additional, Virtuoso, Antonella, additional, Scagnoli, Simone, additional, Pisegna, Simona, additional, Alesini, Daniele, additional, Sini, Valentina, additional, Orlandi, Armando, additional, Fabi, Alessandra, additional, Piacentini, Federico, additional, Moscetti, Luca, additional, D’Auria, Giuliana, additional, Gamucci, Teresa, additional, Mazzotta, Marco, additional, Pizzuti, Laura, additional, Vici, Patrizia, additional, Cretella, Elisabetta, additional, Scavina, Paola, additional, La Cesa, Annalisa, additional, Persano, Mara, additional, Atzori, Francesco, additional, and Ruggeri, Enzo Maria, additional

Published
2023
Full Text
View/download PDF

26. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Author

Persano, Mara, primary, Rimini, Margherita, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shigeo, Shimose, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Presa, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Piscaglia, Fabio, additional, Iavarone, Massimo, additional, Di Costanzo, Giuseppe, additional, Marra, Fabio, additional, Cabibbo, Giuseppe, additional, Foschi, Francesco, additional, Siletta, Marianna, additional, Cascinu, Stefano, additional, Scartozzi, Mario, additional, and Gardini, Andrea Casadei, additional

Published
2023
Full Text
View/download PDF

27. Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, primary, Persano, Mara, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shigeo, Shimose, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Lonardi, Sara, additional, Piscaglia, Fabio, additional, Chon, Hong Jae, additional, Masi, Gianluca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

28. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment

Author

Spanu, Dario, Pretta, Andrea, Lai, Eleonora, Persano, Mara, Donisi, Clelia, Mariani, Stefano, Dubois, Marco, Migliari, Marco, Saba, Giorgio, Ziranu, Pina, Pusceddu, Valeria, Puzzoni, Marco, Astara, Giorgio, and Scartozzi, Mario

Subjects
Science & Technology, Gastroenterology & Hepatology, Hepatology, Hepatocellular carcinoma, Gut-liver axis, Carcinogenesis, TRANSPLANTATION, TOLL-LIKE RECEPTOR-4, BREAST-CANCER CELLS, Gut microbiota, METABOLISM, CLOSTRIDIUM-DIFFICILE INFECTION, GUT MICROBIOME, Fecal microbiota transplantation, Immune checkpoint inhibitors, ALCOHOLIC LIVER-DISEASE, INTESTINAL MICROBIOTA, OBESITY, FECAL MICROBIOTA, Life Sciences & Biomedicine
Abstract

Gut microbiota plays an essential role in host homeostasis. It is involved in several physiological processes such as nutrients digestion and absorption, maintenance of intestinal epithelial barrier integrity and immune system self-tolerance. Especially the gut microbiota is assumed to play a crucial role in many gastrointestinal, pancreatic and liver disorders. Its role in hepatic carcinogenesis is also gaining increasing interest, especially regarding the development of therapeutic strategies. Different studies are highlighting a link between some bacterial strains and liver disease, including hepatocellular carcinoma (HCC). Indeed, HCC represents an interesting field of research in this perspective, due to the gut-liver axis, to the implication of microbiota in the immune system and to the increasing number of immunotherapy agents investigated in this tumour. Thus, the assessment of the role of microbiota in influencing clinical outcome for patients treated with these drugs is becoming of increasing importance. Our review aims to give an overview on the relationship between microbiota and HCC development/progression and treatment. We focus on potential implications on the available treatment strategies and those under study in the various stages of disease. We highlight the pathogenic mechanisms and investigate the underlying molecular pathways involved. Moreover, we investigate the potential prognostic and/or predictive role of microbiota for target therapies, immune checkpoint inhibitors and loco-regional treatment. Finally, given the limitation of current treatments, we analyze the gut microbiota-mediated therapies and its potential options for HCC treatment focusing on fecal microbiota transplantation. ispartof: WORLD JOURNAL OF HEPATOLOGY vol:14 issue:7 pages:1319-1332 ispartof: location:United States status: published

Published
2022

29. New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression

Author

Ziranu, Pina, primary, Aimola, Valentina, additional, Pretta, Andrea, additional, Dubois, Marco, additional, Murru, Raffaele, additional, Liscia, Nicole, additional, Cau, Flaviana, additional, Persano, Mara, additional, Deias, Giulia, additional, Palmas, Enrico, additional, Loi, Francesco, additional, Migliari, Marco, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Lai, Eleonora, additional, Cascinu, Stefano, additional, Faa, Gavino, additional, and Scartozzi, Mario, additional

Published
2023
Full Text
View/download PDF

30. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.

Author

Rimini, Margherita, primary, Casadei-Gardini, Andrea, additional, Persano, Mara, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Rimassa, Lorenza, additional, Presa, Josè, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Tovoli, Francesco, additional, Scartozzi, Mario, additional, Burgio, Valentina, additional, Cascinu, Stefano, additional, and Cucchetti, Alessandro, additional

Published
2023
Full Text
View/download PDF

31. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Rimini, Margherita, primary, Persano, Mara, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa Ramos, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Stefanini, Bernardo, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Montes, Margarida, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Hiraoka, Atsushi, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Burgio, Valentina, additional, Della Corte, Angelo, additional, Ratti, Francesca, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

32. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience

Author

Rimini, Margherita, primary, Burgio, Valentina, additional, Antonuzzo, Lorenzo, additional, Rimassa, Lorenza, additional, Oneda, Ester, additional, Soldà, Caterina, additional, Cito, Pasqua, additional, Nasti, Guglielmo, additional, Lavacchi, Daniele, additional, Zanuso, Valentina, additional, Rizzato, Mario Domenico, additional, Zaniboni, Alberto, additional, Ottaiano, Alessandro, additional, Persano, Mara, additional, Cornara, Noemi, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

34. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, primary, Rimini, Margherita, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Rimassa, Lorenza, additional, Presa, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Tovoli, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Pressiani, Tiziana, additional, Kawaguchi, Takumi, additional, Montes, Margarida, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Hiraoka, Atsushi, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Iavarone, Massimo, additional, Di Costanzo, Giovanni, additional, Marra, Fabio, additional, Scartozzi, Mario, additional, Tamburini, Emiliano, additional, Cabibbo, Giuseppe, additional, Foschi, Francesco Giuseppe, additional, Silletta, Marianna, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Cammarota, Antonella, additional, Burgio, Valentina, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2022
Full Text
View/download PDF

35. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment

Author

Pretta, Andrea, primary, Ziranu, Pina, additional, Giampieri, Riccardo, additional, Donisi, Clelia, additional, Cimbro, Erika, additional, Spanu, Dario, additional, Lai, Eleonora, additional, Pecci, Federica, additional, Balconi, Francesca, additional, Lupi, Alessio, additional, Pozzari, Marta, additional, Persano, Mara, additional, Murgia, Sara, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Berardi, Rossana, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

36. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors

Author

Ziranu, Pina, primary, Pretta, Andrea, additional, Pozzari, Marta, additional, Maccioni, Antonio, additional, Badiali, Manuela, additional, Fanni, Daniela, additional, Lai, Eleonora, additional, Donisi, Clelia, additional, Persano, Mara, additional, Gerosa, Clara, additional, Puzzoni, Marco, additional, Bardanzellu, Fabio, additional, Ambu, Rossano, additional, Pusceddu, Valeria, additional, Dubois, Marco, additional, Cerrone, Giulia, additional, Migliari, Marco, additional, Murgia, Sara, additional, Spanu, Dario, additional, Pretta, Gianluca, additional, Aimola, Valentina, additional, Balconi, Francesca, additional, Murru, Stefania, additional, Faa, Gavino, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

37. Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib

Author

Rimini, Margherita, primary, Kang, Wonseok, additional, Burgio, Valentina, additional, Persano, Mara, additional, Aoki, Tamoko, additional, Shimose, Shigeo, additional, Tada, Toshifumi, additional, Kumada, Takashi, additional, Sho, Takuya, additional, Lai, Eleonora, additional, Celsa, Ciro, additional, Campani, Claudia, additional, Tonnini, Matteo, additional, Tamburini, Emiliano, additional, Hiraoka, Atsushi, additional, Takaguchi, Koichi, additional, Nishida, Naoshi, additional, Iwamoto, Hideki, additional, Itobayashi, Ei, additional, Tsuji, Kunihiko, additional, Sakamoto, Naoya, additional, Ishikawa, Toru, additional, Toyoda, Hidenori, additional, Kudo, Masatoshi, additional, Kawaguchi, Takumi, additional, Hatanaka, Takeshi, additional, Nouso, Kazugiro, additional, Suda, Goki, additional, Cabibbo, Giuseppe, additional, Marra, Fabio, additional, Della Corte, Angelo, additional, Ratti, Francesca, additional, Pedica, Federica, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei‐Gardini, Andrea, additional

Published
2022
Full Text
View/download PDF

38. Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.

Author

Pretta, Andrea, primary, Cimbro, Erika, additional, Giampieri, Riccardo, additional, Spanu, Dario, additional, Lai, Eleonora, additional, Pecci, Federica, additional, Balconi, Francesca, additional, Lupi, Alessio, additional, Pozzari, Marta, additional, Murgia, Sara, additional, Bardanzellu, Fabio, additional, Maccioni, Antonio, additional, Contu, Fabiana, additional, Persano, Mara, additional, Donisi, Clelia, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Ziranu, Pina, additional, Berardi, Rossana, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

39. Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.

Author

Pretta, Andrea, primary, Spanu, Dario, additional, Giampieri, Riccardo, additional, Lai, Eleonora, additional, Cimbro, Erika, additional, Pecci, Federica, additional, Balconi, Francesca, additional, Lupi, Alessio, additional, Pozzari, Marta, additional, Murgia, Sara, additional, Bardanzellu, Fabio, additional, Maccioni, Antonio, additional, Contu, Fabiana, additional, Persano, Mara, additional, Donisi, Clelia, additional, Valeria, Pusceddu, additional, Puzzoni, Marco, additional, Ziranu, Pina, additional, Berardi, Rossana, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

40. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.

Author

Pretta, Andrea, Ziranu, Pina, Giampieri, Riccardo, Donisi, Clelia, Cimbro, Erika, Spanu, Dario, Lai, Eleonora, Pecci, Federica, Balconi, Francesca, Lupi, Alessio, Pozzari, Marta, Persano, Mara, Murgia, Sara, Pusceddu, Valeria, Puzzoni, Marco, Berardi, Rossana, and Scartozzi, Mario

Abstract

Association between pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus (DM2) has long been evaluated. Indeed, DM2 can be both an epiphenomenon of PDAC and a risk factor. The present study aimed to investigate the correlation between overall survival (OS) and antidiabetic drugs in patients with metastatic pancreatic ductal adenocarcinoma and DM2. Data from 232 patients were collected retrospectively from 2014 to 2021. 174 from AOU Cagliari Medical Oncology and 58 from AOU Ancona Medical Oncology. All patients received gemcitabine plus nab-paclitaxel first-line chemotherapy. We aimed to evaluate the correlation between DM2, anti-diabetic medications and overall survival. Survival distribution was assessed by Kaplan-Meier curves. Median age was 68±9, 127 (55%) were male. 138/232 (59%) patients were not affected by DM2, 94/232 (41%) were affected by DM2. 57 were insulin-treated and 37 were metformin-treated. DM2 treated patients showed an higher median overall survival (26 vs 12 months, p = 0,0002). Among DM2 patients insulin-treated and metformin-treated showed an mOS of 21 months and 33 months, respectively. Results showed a correlation between treated DM2 and higher mOS in patients with mPDAC. Limitations due to retrospective data collection must be considered. Further studies in this setting are needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients

Author

Mariani, Stefano, primary, Puzzoni, Marco, additional, Giampieri, Riccardo, additional, Ziranu, Pina, additional, Pusceddu, Valeria, additional, Donisi, Clelia, additional, Persano, Mara, additional, Pinna, Giovanna, additional, Cimbro, Erika, additional, Parrino, Alissa, additional, Spanu, Dario, additional, Pretta, Andrea, additional, Lai, Eleonora, additional, Liscia, Nicole, additional, Lupi, Alessio, additional, Giglio, Enrica, additional, Palomba, Grazia, additional, Casula, Milena, additional, Pisano, Marina, additional, Palmieri, Giuseppe, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

42. Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer.

Author

Pretta, Andrea, primary, Donisi, Clelia, additional, Persano, Mara, additional, Pinna, Giovanna, additional, Cimbro, Erika, additional, Parrino, Alissa, additional, Aimola, Valentina, additional, Spanu, Dario, additional, Cerrone, Giulia, additional, Deidda, Simona, additional, Deidda, Maria Assunta, additional, Lai, Eleonora, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Ziranu, Pina, additional, Barbara, Raffaele, additional, Restivo, Angelo, additional, Zorcolo, Luigi, additional, Faa, Gavino, additional, and Scartozzi, Mario, additional

Published
2022
Full Text
View/download PDF

43. Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?

Author

Persano, Mara, Casadei-Gardini, Andrea, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Rimini, Margherita

Subjects
PROGNOSIS, HEPATOCELLULAR carcinoma, INDIVIDUALIZED medicine, THERAPEUTICS
Abstract

Lenvatinib was the first drug approved in 2017 for first-line treatment of hepatocarcinoma (HCC) after 10 years of Sorafenib as exclusive standard of care. The therapeutic armamentarium has recently expanded following the approval of atezolizumab plus bevacizumab. Numerous studies have been conducted during the past 5 years on Lenvatinib use in real-world settings in an effort to determine prognostic and predictive factors of Lenvatinib efficacy. In order to choose the most effective therapeutic approach, it may be helpful to summarize these results in this review. A subgroup that appears to benefit most from Lenvatinib therapy are patients with non-viral cirrhosis. This aspect is of great importance today considering the increase in NASH prevalence. Also, a significant proportion of BCLC B patients appear to respond well to Lenvatinib therapy. The biological heterogeneity highlighted in HCC patients, along with the growing number of therapeutic options, makes the identification of stratification tools able to define which patients are more likely to respond to a treatment rather than another one of crucial interest. Further investigation deepening the biological pathways underlying HCC carcinogenesis are of particular interest in order to pave the way for precision medicine even for HCC patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Uncovering key targets of success for immunotherapy in pancreatic cancer

Author

Pretta, Andrea, primary, Lai, Eleonora, additional, Persano, Mara, additional, Donisi, Clelia, additional, Pinna, Giovanna, additional, Cimbro, Erika, additional, Parrino, Alissa, additional, Spanu, Dario, additional, Mariani, Stefano, additional, Liscia, Nicole, additional, Dubois, Marco, additional, Migliari, Marco, additional, Impera, Valentino, additional, Saba, Giorgio, additional, Pusceddu, Valeria, additional, Puzzoni, Marco, additional, Ziranu, Pina, additional, and Scartozzi, Mario, additional

Published
2021
Full Text
View/download PDF

45. Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

Author

Giampieri, Riccardo, primary, Lupi, Alessio, additional, Ziranu, Pina, additional, Bittoni, Alessandro, additional, Pretta, Andrea, additional, Pecci, Federica, additional, Persano, Mara, additional, Giglio, Enrica, additional, Copparoni, Cecilia, additional, Crocetti, Sonia, additional, Mandolesi, Alessandra, additional, Faa, Gavino, additional, Coni, Pierpaolo, additional, Scartozzi, Mario, additional, and Berardi, Rossana, additional

Published
2021
Full Text
View/download PDF

46. Molecular-driven treatment for biliary tract cancer: the promising turning point

Author

Persano, Mara, primary, Puzzoni, Marco, additional, Ziranu, Pina, additional, Pusceddu, Valeria, additional, Lai, Eleonora, additional, Pretta, Andrea, additional, Donisi, Clelia, additional, Pinna, Giovanna, additional, Spanu, Dario, additional, Cimbro, Erika, additional, Parrino, Alissa, additional, Liscia, Nicole, additional, Mariani, Stefano, additional, Dubois, Marco, additional, Migliari, Marco, additional, and Scartozzi, Mario, additional

Published
2021
Full Text
View/download PDF

47. Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.

Author

Mariani, Stefano, primary, Puzzoni, Marco, additional, Liscia, Nicole, additional, Impera, Valentino, additional, Pretta, Andrea, additional, Tolu, Simona, additional, Pireddu, Anna Grazia, additional, Persano, Mara, additional, Musio, Francesca, additional, Donisi, Clelia, additional, Pinna, Giovanna, additional, Lai, Eleonora, additional, Demurtas, Laura, additional, Ziranu, Pina, additional, Pusceddu, Valeria, additional, Pisano, Marina, additional, Palomba, Grazia, additional, Casula, Milena, additional, Palmieri, Giuseppe, additional, and Scartozzi, Mario, additional

Published
2021
Full Text
View/download PDF

48. THU-145 - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shigeo, Shimose, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Piscaglia, Fabio, Iavarone, Massimo, Di Costanzo, Giuseppe, Marra, Fabio, Cabibbo, Giuseppe, Foschi, Francesco, Siletta, Marianna, Cascinu, Stefano, Scartozzi, Mario, and Gardini, Andrea Casadei

Published
2023
Full Text
View/download PDF

49. THU-143 - Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shigeo, Shimose, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Lonardi, Sara, Piscaglia, Fabio, Chon, Hong Jae, Masi, Gianluca, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

50. Immune Checkpoint Inhibitors in the Treatment of HCC

Author

Donisi, Clelia, primary, Puzzoni, Marco, additional, Ziranu, Pina, additional, Lai, Eleonora, additional, Mariani, Stefano, additional, Saba, Giorgio, additional, Impera, Valentino, additional, Dubois, Marco, additional, Persano, Mara, additional, Migliari, Marco, additional, Pretta, Andrea, additional, Liscia, Nicole, additional, Astara, Giorgio, additional, and Scartozzi, Mario, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results